Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables. (PolyIran-L)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01245608|
Recruitment Status : Active, not recruiting
First Posted : November 22, 2010
Last Update Posted : March 6, 2018
The primary purpose of this study is to determine the effects of a fixed dose combination of valsartan, hydrochlorothiazide, atorvastatin and aspirin (PolyPill) on prevention of cardiovascular events in adults older than 50.
Various liver-related variables will also be recorded which will allow studying the effects of PolyPill on the liver and the effect of liver diseases such as nonalcoholic steatohepatitis on cardiovascular events and the protective effect of PolyPill.
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Diseases||Drug: Polypill||Phase 3|
2400 subjects will be randomly selected from participants of the Golestan Cohort Study (GCS) who are living in Gonbad and are over 50 years old. These subjects will be randomized to either receive PolyPill or no treatment.
Those agreeing to the study will undergo additional measurements (in addition to the baseline measurements performed in the GCS) including liver-related tests such as liver enzyme levels, abdominal ultrasonography and liver stiffness measurement. Some additional tests such as color doppler ultrasonography of carotid vessels will also be performed.
Subjects in the PolyPill arm who have no contraindication for the components of the pill will receive a single daily dose of PolyPill for 5 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.|
|Actual Study Start Date :||October 2011|
|Actual Primary Completion Date :||January 2018|
|Estimated Study Completion Date :||September 2018|
Single daily dose of PolyPill and 6-monthly visits
Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
Other Name: PolyPill 4-2
No Intervention: Control
Only 6-monthly visits
- Major Cardiovascular Events [ Time Frame: 5 years ]The first occurrence of hospitalization for acute coronary syndrome (non-fatal myocardial infarction and unstable angina), fatal myocardial infarction, sudden death, new-onset heart failure, coronary artery revascularization procedures and stroke (fatal or non-fatal).
- Side effects [ Time Frame: 5 years ]questionnaire
- Changes in liver enzyme levels [ Time Frame: 5 years ]AST, ALT
- Changes in liver stiffness [ Time Frame: 5 years ]As measured by fibroscan
- Compliance [ Time Frame: 5 years ]Pill count
- Fat deposition [ Time Frame: 5 years ]Visceral Adipose Tissue thickness (VAT), Subcutaneous Adipose Tissue thickness (SAT) and carotid intima-media thickness (IMT)
- All-cause Mortality [ Time Frame: 5 years ]Yearly follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01245608
|Iran, Islamic Republic of|
|Golestan Cohort Center|
|Gonbad, Golestan, Iran, Islamic Republic of|
|Study Chair:||Reza Malekzadeh, M.D.||Tehran University of Medical Sciences|
|Principal Investigator:||Shahin Merat, M.D.||Tehran University of Medical Sciences|